Vatalanib ((PTK787 or ZK 222584, cpg-79787) is a novel, potent and orally bioavailable inhibitor of VEGFR2/KDR with IC50 of 37 nM in a cell-free assay, it is less potent against VEGFR1/Flt-1, and is 18-fold against VEGFR3/Flt-4. It is an anilinophthalazine analog with potential antineoplastic activity. Vatalanib binds to and inhibits the protein kinase domain of VEGFR 1 and 2. This agent also binds to and inhibits related receptor tyrosine kinases, including PDGF receptor, c-Kit, and c-Fms.

纯度：≥98%

CAS：212141-54-3